Kuznicki Law is investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 million shares of common stock of Aditxt and a cash payment of $250,000 at a secondary closing. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.